News

Article

Five Under 5: Top Oncology Videos for the Week of 1/26

Author(s):

Key Takeaways

  • Gene expression profiling links claudin 18 and MUC1 in gastrointestinal cancers, suggesting potential targeted therapy developments.
  • A consensus report from the National Academies of Sciences, Engineering, and Medicine offers insights into gynecologic oncology.
SHOW MORE

The top 5 videos of the week cover insights in gastrointestinal cancers, gynecologic malignancies, and blood cancers.

Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.

Here’s what you may have missed:

Association Between MUC1 and CLDN18 in GI Cancers: Aditya Shreenivas, MD, MS

Association Between MUC1 and CLDN18 in GI Cancers: Aditya Shreenivas, MD, MS

Aditya Shreenivas, MD, MS, an assistant professor in the Department of Medical Oncology & Therapeutics Research at City of Hope, in California, spotlighted data from a gene expression profiling analysis of the association between claudin 18 and MUC1 in gastrointestinal cancers, and their potential implications for targeted therapy development.

Assessment of Women’s Health Research at the NIH: Angeles Alvarez Secord, MD, MHSc

Assessment of Women’s Health Research at the NIH: Angeles Alvarez Secord, MD, MHSc

Angeles Alvarez Secord, MD, MHSc, a professor of obstetrics and gynecology at Duke Cancer Institute, in North Carolina, reviewed findings from a consensus report published by the National Academies of Sciences, Engineering, and Medicine committee. Check out more insights from the 2025 SGO Winter Meeting.

Effect of IVIG on Infection Risk in R/R Multiple Myeloma: Mansi R. Shah, MD

Effect of IVIG on Infection Risk in R/R Multiple Myeloma: Mansi R. Shah, MD

Mansi R. Shah, MD, an assistant professor of medicine in the Division of Blood Disorders at Rutgers Cancer Institute of New Jersey, Robert Wood Johnson (RWJ) Medical School and hematologist/oncologist at RWJ University Hospital, detailed findings from a study presented at the 2024 ASH Annual Meeting, which examined the effects of intravenous immunoglobulin supplementation on infections in patients with relapsed/refractory multiple myeloma treated with teclistamab-cqyv (Tecvayli).

PREEMPT CRC Blood-Based Assay for Average-Risk CRC: Aasma Shaukat, MD, MPH

PREEMPT CRC Blood-Based Assay for Average-Risk CRC: Aasma Shaukat, MD, MPH

Aasma Shaukat, MD, MPH, Robert M. and Mary H. Glickman Professor of Medicine in the Department of Medicine and professor in the Department of Population Health at NYU Grossman School of Medicine; director of Outcomes Research in the Division of Gastroenterology and Hepatology; and codirector of Translational Research Education and Careers at NYU Langone Health, in New York, discussed the performance of a blood-based colorectal cancer screening test adjusted to the US census age and sex distribution. Data from the test were shared at the 2025 Gastrointestinal Cancers Symposium.

ual IRAK4/FLT3 Inhibition With Emavusertib in MDS and AML: Guillermo Garcia-Manero, MD

Dual IRAK4/FLT3 Inhibition With Emavusertib in MDS and AML: Guillermo Garcia-Manero, MD

Guillermo Garcia-Manero, MD, professor and chief of the Section of Myelodysplastic Syndromes, deputy chair of Translational Research, fellowship program director in the Department of Leukemia of the Division of Cancer Medicine, chair and faculty senate at The University of Texas MD Anderson Cancer Center, in Houston, explained the rationale for investigating the dual inhibition of IRAK4 and FLT3 with emavusertib (CA-4948) in myelodysplastic syndrome and acute myeloid leukemia.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
Michael R. Bishop, MD
Marwan G. Fakih, MD, discusses the FDA approval of sotorasib with panitumumab for the treatment of adult patients with KRAS G12C–mutated metastatic colorectal cancer.
C. Ola Landgren, MD, PhD
Kathleen N. Moore, MD, MS
Dana M. Chase, MD
Kanwal PS Raghav, MBBS, MD
R. Tyler Hillman, MD, PhD, of The University of Texas MD Anderson Cancer Center
Angeles Alvarez Secord, MD, MHSc, of Duke Cancer Institute